Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851186 | 0.86 | — | — | |
| SCHEMBL2849359 | 0.81 | ALDH1A1 (0.45) | PTPN1NPC1TP53CYP1A2CYP3A4 | |
| SCHEMBL3557121 | 0.77 | THRB (0.39) | NPC1TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14556337 | 0.71 | PTPN1 (0.32) | PTPN1NPC1TP53CYP1A2CYP3A4 | |
| SCHEMBL2851591 | 0.67 | CASP1 (0.39) | NPC1TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2851376 | 0.65 | SCN9A (0.34) | NPC1TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17144343 | 0.65 | NOTUM (0.46) | NPC1TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30405765 | 0.65 | NOTUM (0.46) | NPC1TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1615811 | 0.64 | NPC1 (0.46) | NPC1TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16372354 | 0.64 | LCK (0.46) | NPC1TP53CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666883-B2 | 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-02-23 | — | — | US | claimed |
| EP-1924558-B1 | AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2010-01-13 | — | — | EP | claimed |
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-05-24 | — | — | US | claimed |
| US-7666883-B2 | 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-02-23 | — | — | US | disclosed |
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | HBS1L, SSBP1, QARS1 | PTPN1 4206/4885NPC1 2568/4885TP53 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.